Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RCUS vs NTLA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NTLA Captures Overall Composite Edge (50.7 HOLD vs 48.4 HOLD), While RCUS Leads 5–1 on Growth & Valuation Pillars
NTLA Overall Winner
6-Pillar Tally: RCUS 5 – 1 NTLA
Matrix Metrics: RCUS 2 – 5 NTLA
As of Nov 16, 2026, Intellia Therapeutics, Inc (NTLA) captures the overall head-to-head institutional edge over Arcus Biosciences, Inc. (RCUS) on higher Unified Composite conviction (50.7/100 HOLD vs. 48.4/100 HOLD) after splitting the core matrix 5–2 (led by R&D & Supply-Chain Moat), while RCUS wins 5–1 across the 6-pillar growth and valuation breakdown. RCUS trades at $16.97 (N/M Forward P/E, -475.0% operating margin) versus NTLA at $10.00 (N/M Forward P/E, -826.0% operating margin).
- Growth vs. Quality Trade-Off: NTLA earns the overall head-to-head edge with a stronger Unified Composite Score (50.7/100 HOLD vs. RCUS 48.4/100 HOLD) and 2.30β · 87% Vol risk profile, whereas RCUS leads top-line expansion (-65.4% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: RCUS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.3); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About RCUS vs NTLA
RCUS
Arcus Biosciences, Inc.
$16.97
-2.64% 1D
Market Cap
$2.6B
TTM Revenue
$100M
Forward P/E
N/M
Beta / 30D Vol
1.56β · 90% Vol
Unified Composite Score
48.4
HOLD
Tech 48.0
Fund 59.0
Flow 68.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
NTLA
Head-to-Head Winner
Intellia Therapeutics, Inc
$10.00
+3.09% 1D
Market Cap
$1.5B
TTM Revenue
$53M
Forward P/E
N/M
Beta / 30D Vol
2.30β · 87% Vol
Unified Composite Score
50.7
HOLD
Tech 47.0
Fund 55.0
Flow 59.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (RCUS 5 – 1 NTLA)
1. Valuation Multiples
RCUS
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
25.2x
29.1x
2. Growth & Scale
RCUS
Revenue Growth (YoY)
-65.4%
-48.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$100M
$53M
Market Cap
$2.6B
$1.5B
3. Profitability & Quality
RCUS
Gross Margin
N/A
N/A
Operating Margin
-475.0%
-826.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-114.1%
-62.6%
4. Balance Sheet & Cash Flow
RCUS
Cash Generation (TTM)
-$466M
-$358M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$35M Net Cash
$74M Net Debt (0.38x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
RCUS
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
43.1% (1st %ile)
101.3% (78th %ile)
Put/Call OI Skew
0.08x (Call-Skewed)
0.42x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
NTLA
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: RCUS (2) vs NTLA (5)| Institutional Metric | RCUS | NTLA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.6B | $1.5B | RCUS | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -65.4% | -48.0% | NTLA | |
| Operating Margin (TTM) | -475.0% | -826.0% | RCUS | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -114.1% | -62.6% | NTLA | |
| 52-Week Range Position | 1% ($17–$32) | 20% ($8–$18) | NTLA | |
| Beta / 30D Volatility | 1.56β · 90% Vol | 2.30β · 87% Vol | NTLA | |
| Unified Institutional Score | 48.4 / 100 (HOLD) | 50.7 / 100 (HOLD) | NTLA | |
| Trailing 12M Revenue (USD) | $100M | $53M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 25.2x EV/Rev | N/M PEG · 29.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$466M ($35M Net Cash) | -$358M ($74M Net Debt (0.38x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
NTLA +10.85 pp
3M Horizon
NTLA +28.7 pp
6M Horizon
NTLA +6.28 pp
1Y Horizon
NTLA +29.59 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RCUS Revenue | NTLA Revenue | RCUS Op. Margin | NTLA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $10M | $30M | -656.8% | -298.6% | NTLA |
| FY2019 | $10M | $40M | -591.4% | -246.8% | NTLA |
| FY2020 | $80M | $60M | -159.0% | -235.5% | RCUS |
| FY2021 | $380M | $30M | 14.1% | -810.4% | RCUS |
| FY2022 | $40M | $50M | -736.8% | -879.0% | RCUS |
| FY2023 | $40M | $40M | -918.9% | -1420.5% | RCUS |
| FY2024 | $50M | $60M | -647.1% | -923.1% | RCUS |
| FY2025 | $30M | $70M | -1169.7% | -651.7% | NTLA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
RCUS
BREAKDOWN
Current IV
43.1%
IV Percentile
1st %ile
Put/Call OI Skew
0.08x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact RCUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NTLA
BREAKDOWN
Current IV
101.3%
IV Percentile
78th %ile
Put/Call OI Skew
0.42x (Call-Skewed)
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
RCUS Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
NTLA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published · CRISPR / Gene Editing
Investor FAQ RCUS vs NTLA Key Questions & Quantitative Answers
As of Nov 16, 2026, Intellia Therapeutics, Inc (NTLA) captures the overall head-to-head institutional edge over Arcus Biosciences, Inc. (RCUS) on higher Unified Composite conviction (50.7/100 HOLD vs. 48.4/100 HOLD) after splitting the core matrix 5–2 (led by R&D & Supply-Chain Moat), while RCUS wins 5–1 across the 6-pillar growth and valuation breakdown. RCUS trades at $16.97 (N/M Forward P/E, -475.0% operating margin) versus NTLA at $10.00 (N/M Forward P/E, -826.0% operating margin). Growth vs. Quality Trade-Off: NTLA earns the overall head-to-head edge with a stronger Unified Composite Score (50.7/100 HOLD vs. RCUS 48.4/100 HOLD) and 2.30β · 87% Vol risk profile, whereas RCUS leads top-line expansion (-65.4% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RCUS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.3); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RCUS leads the Growth & Scale pillar: RCUS posts -65.4% YoY revenue growth and +0.0% YoY earnings growth on $100M TTM revenue (N/A gross margin, -475.0% operating margin), compared with NTLA at -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RCUS cumulative revenue shifted +200.0% while NTLA shifted +133.3%. In operating R&D and SG&A reinvestment, RCUS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NTLA.
RCUS screens cheaper on headline valuation multiples. RCUS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 25.2x EV/Revenue (unreported FCF margin), whereas NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RCUS (-114.1% ROE) versus NTLA (-62.6% ROE) capital efficiency.
In options market volatility and institutional positioning, RCUS carries 43.1% implied volatility (1st %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 90% Vol realized risk). By comparison, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NTLA vs RCUS · Reverse Pair
RCUS vs SNDX
· Sector Peer
RCUS vs ARVN
· Sector Peer
RCUS vs DNLI
· Sector Peer
NTLA vs CRSP
· Sector Peer
NTLA vs BEAM
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem